Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Resonance HealthASX:RHT +7.69% 3-Year EBITDA Growth Rate is 12.60% as of Dec. 2025, which is 100% above its 10-year median of 6.30. The stock has 8 warning signs investors should review. Among 527 Healthcare Providers & Services companies, Resonance Health ranks better than 54.46% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 12.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Resonance Health was 86.50% per year. The lowest was -106.20% per year. And the median was 6.30% per year.
Resonance Health (ASX:RHT) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Resonance Health 3-Year EBITDA Growth Rate Related Terms
ASX:RHT vs VEEV, BTSG, HQY: 3-Year EBITDA Growth Rate Comparison
For the Health Information Services subindustry, Resonance Health's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Resonance Health 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Resonance Health's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Resonance Health's 3-Year EBITDA Growth Rate falls into.
Resonance Health 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 12.60% mean?
Resonance Health (ASX:RHT) has a 3-Year EBITDA Growth Rate of 12.60% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Resonance Health and its competitors. This is 100% above median its historical median of 6.30. According to the industry distribution chart, Resonance Health ranks #240 out of 527 companies in the Healthcare Providers & Services industry, placing it in the top 45.5%.
Is Resonance Health's 3-Year EBITDA Growth Rate too high?
Resonance Health's current 3-Year EBITDA Growth Rate of 12.60% is 100% above median its 10-year median of 6.30. The Healthcare Providers & Services industry median 3-Year EBITDA Growth Rate is 10.20. Resonance Health's value of 12.60% is 23.5% above this industry median. Based on the distribution chart, Resonance Health ranks #240 out of 527 companies in the Healthcare Providers & Services industry, which is above the industry midpoint.
How does Resonance Health's 3-Year EBITDA Growth Rate compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Resonance Health ranks #240 out of 527 companies for 3-Year EBITDA Growth Rate. This puts Resonance Health in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 10.20. Resonance Health's value of 12.60% is 23.5% above this benchmark. While the company's 10-year median is 6.30 vs. the industry median of 10.20, Resonance Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 10.20, based on 527 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Resonance Health's current 3-Year EBITDA Growth Rate of 12.60% is 23.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Resonance Health and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 10.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Resonance Health's current 3-Year EBITDA Growth Rate is 12.60%, which is 100% above median its own 10-year median of 6.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Resonance Health stock overvalued right now?
Based on GuruFocus' analysis, Resonance Health (ASX:RHT) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.12, compared to a current price of A$0.06 — trading 53.3% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 12.60%, which is 100% above median its 10-year median of 6.30 and 23.5% above the Healthcare Providers & Services industry median of 10.20. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Resonance Health (ASX:RHT), the current 3-Year EBITDA Growth Rate is 12.60% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Resonance Health Ltd is engaged in the development and commercialisation of software-as-medical-device (SaMD) technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. The Group's core SaMD product is FerriScan, a non-invasive liver analysis technology used for the assessment of iron in the liver. The Company also has several AI-assisted SaMDs including FerriSmart, HepaFatSmart, and LiverSmart. Its business segments are; SaMD1 which derives key revenue, Corporate, TrialsWest, and Resonance Clinica. Geographically, it generates maximum revenue from the Asia Pacific region and the rest from North America, and Europe, Middle East and Africa (EMEA) regions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:RHT has been successfully added to your 
